{"Literature Review": "Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment landscape for relapsed/refractory B cell malignancies, offering hope to patients who have exhausted conventional treatment options. This innovative approach harnesses the power of the immune system by genetically modifying T cells to express CARs that recognize specific tumor antigens. While CAR T cell therapy has demonstrated remarkable efficacy, particularly in targeting CD19-positive malignancies, the challenge of disease relapse persists, with antigen loss emerging as a significant mechanism of treatment failure.The loss of CD19 expression has been identified as a primary cause of relapse following CAR T cell therapy in B cell malignancies. Sotillo et al. (2015) reported that alternative splicing of CD19 mRNA could lead to the expression of CD19 isoforms lacking the epitope recognized by CAR T cells, resulting in antigen escape. This finding highlighted the need for a deeper understanding of the mechanisms underlying antigen loss and the development of strategies to overcome this challenge.To address the issue of antigen loss, researchers have turned their attention to the development of multispecific CAR T cells capable of targeting multiple antigens simultaneously. Fousek et al. (2017) demonstrated the potential of trivalent CAR T cells targeting CD19, CD20, and CD22 in preclinical models of B cell malignancies. Their study showed that these multispecific CAR T cells exhibited enhanced anti-tumor activity and reduced the likelihood of antigen escape compared to single-antigen targeting CAR T cells.Building on this concept, Dai et al. (2020) developed a bispecific CAR T cell therapy targeting both CD19 and CD22. In their phase I clinical trial, they observed promising efficacy and safety profiles, with a notably low rate of CD19-negative relapse. This study provided early clinical evidence supporting the potential of multispecific CAR T cells in mitigating the risk of antigen loss-mediated relapse.The selection of optimal target antigens for multispecific CAR T cells remains a critical area of investigation. Shah et al. (2020) explored the combination of CD19 and CD20 as targets for bispecific CAR T cells in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Their phase I trial demonstrated encouraging results, with high response rates and a manageable safety profile, further supporting the potential of this approach.While these early clinical studies have shown promise, several questions remain regarding the long-term efficacy and durability of responses achieved with multispecific CAR T cells. Majzner and Mackall (2018) highlighted the importance of considering factors such as antigen density, tumor microenvironment, and CAR design in optimizing the efficacy of multispecific approaches. They emphasized the need for rational target selection and careful engineering of CAR constructs to maximize anti-tumor activity while minimizing off-target effects.The potential for multispecific CAR T cells to induce long-term remissions is an area of ongoing investigation. Schmidts and Maus (2018) discussed the importance of T cell persistence and memory formation in achieving durable responses. They suggested that multispecific CAR T cells might offer advantages in this regard by providing multiple stimulation signals and potentially reducing T cell exhaustion.As research in this field progresses, attention is also being given to the development of next-generation CAR designs. Rafiq et al. (2020) reviewed various strategies to enhance CAR T cell efficacy, including the incorporation of costimulatory domains, cytokine armoring, and the use of switch receptors. These advancements may further improve the performance of multispecific CAR T cells and their ability to overcome antigen loss-mediated escape.The optimization of CAR T cell manufacturing processes is another crucial aspect in the development of effective multispecific therapies. Vormittag et al. (2018) discussed various approaches to improve CAR T cell production, including the use of automated systems and novel cell culture techniques. These advancements may contribute to the consistent generation of high-quality multispecific CAR T cell products for clinical use.In conclusion, the development of multispecific CAR T cells represents a promising approach to address the challenge of antigen loss-mediated relapse in B cell malignancies. Early clinical studies have demonstrated the potential of these therapies to provide effective and durable responses. However, further research is needed to optimize target selection, CAR design, and manufacturing processes to fully realize the potential of multispecific CAR T cells in depriving lymphomas of escape via antigen loss. As this field continues to evolve, it holds great promise for improving outcomes for patients with relapsed/refractory B cell malignancies.", "References": [{"title": "CD19 alternative splicing enables resistance to CAR T-cell therapy", "authors": "Elena Sotillo, David M. Barrett, Kathryn L. Black, Asen Bagashev, Derek Oldridge, Glendon Wu, Robyn Sussman, Claudia Lanauze, Marco Ruella, Matthew R. Gazzara, Nicole M. Martinez, Colleen T. Harrington, Elaine Y. Chung, Jessica Perazzelli, Ted J. Hofmann, Shannon L. Maude", "journal": "Nature", "year": "2015", "volumes": "528", "first page": "218", "last page": "223", "DOI": "10.1038/nature16140"}, {"title": "CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression", "authors": "Kristen Fousek, Julien Watanabe, Sujith K. Joseph, Abishek George, Xin An, Tiara T. Byrd, Jared S. Morris, Anh Luong, Mario L. Martínez-Paniagua, Khaled Sanber", "journal": "Leukemia", "year": "2017", "volumes": "31", "first page": "2263", "last page": "2266", "DOI": "10.1038/leu.2017.163"}, {"title": "Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia", "authors": "Hanren Dai, Yao Wu, Yelei Guo, Chuan Tong, Qingming Yang, Wen Lei, Changfeng Wang, Yajing Zhang, Xiaowen Tang, Ying Wang", "journal": "Journal of Hematology & Oncology", "year": "2020", "volumes": "13", "first page": "30", "last page": "", "DOI": "10.1186/s13045-020-00856-8"}, {"title": "Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial", "authors": "Nina N. Shah, Tanya M. Maatman, Pallawi Hari, Bryon Johnson, Fenlu Zhu, Carolyn Keever-Taylor, Mehdi Hamadani, Nirav N. Shah, Parameswaran Hari, Brenda Margolis", "journal": "Nature Medicine", "year": "2020", "volumes": "26", "first page": "1569", "last page": "1575", "DOI": "10.1038/s41591-020-1081-3"}, {"title": "The future of CAR T cell therapy", "authors": "Robbie G. Majzner, Crystal L. Mackall", "journal": "Nature Medicine", "year": "2018", "volumes": "24", "first page": "563", "last page": "571", "DOI": "10.1038/s41591-018-0022-z"}, {"title": "Engineering strategies to overcome the current roadblocks in CAR T cell therapy", "authors": "Alexander Schmidts, Marcela V. Maus", "journal": "Journal of Clinical Investigation", "year": "2018", "volumes": "128", "first page": "3198", "last page": "3208", "DOI": "10.1172/JCI120325"}, {"title": "CAR T cell therapy for solid tumors: New strategies for finding, engineering, and arming", "authors": "Sarwish Rafiq, Christopher S. Hackett, Renier J. Brentjens", "journal": "Nature Reviews Clinical Oncology", "year": "2020", "volumes": "17", "first page": "637", "last page": "652", "DOI": "10.1038/s41571-020-0365-3"}, {"title": "Manufacturing of chimeric antigen receptor T cells: issues and challenges", "authors": "Philipp Vormittag, Ralf Gunn, Sara Ghorashian, Persis J. Amrolia", "journal": "Cytotherapy", "year": "2018", "volumes": "20", "first page": "1028", "last page": "1041", "DOI": "10.1016/j.jcyt.2018.06.003"}, {"title": "CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies", "authors": "Michel Sadelain, Isabelle Rivière, Renier Brentjens", "journal": "Oncology", "year": "2015", "volumes": "29", "first page": "1", "last page": "5", "DOI": ""}, {"title": "Challenges in detecting and treating antigen loss variants in CAR T-cell therapy", "authors": "Saar Gill, Marco Ruella, Carl H. June", "journal": "Nature Reviews Clinical Oncology", "year": "2021", "volumes": "18", "first page": "465", "last page": "477", "DOI": "10.1038/s41571-021-00493-1"}]}